Related Experiment Video

Updated: Sep 13, 2025

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

10.8K

Multicenter randomized controlled trial to evaluate the efficacy and safety of probiotic adjunctive therapy for

Elham Bidabadi1, Farahnak Assadi2, Rama Naghshizadian3

  • 1Pediatric Diseases Research Center, Guilan University of Medical Sciences, Rasht, Iran.

Pediatric Nephrology (Berlin, Germany)
|July 28, 2025
PubMed

Insights

Probiotics significantly lowered blood pressure (BP) in children with hypertension when added to standard treatment. This study found probiotics to be safe and effective for pediatric hypertension management.

Area of Science:

  • Pediatric Cardiology
  • Microbiome Research
  • Hypertension Management

Background:

  • Probiotics show promise for adult hypertension but their role in childhood hypertension is unclear.
  • This study addresses the efficacy and safety of probiotics in pediatric primary hypertension.

Purpose of the Study:

  • To evaluate the effectiveness of probiotics as an adjunct therapy for childhood hypertension.
  • To assess the safety profile of probiotics in pediatric patients with hypertension.

Main Methods:

  • A multicenter, randomized, double-blind, placebo-controlled trial was conducted in children with primary hypertension.
  • Participants received either probiotics plus conventional drugs or antihypertensive drugs alone for 4 months.
  • Endpoints included blood pressure reduction and incidence of adverse events.

Main Results:

  • The probiotic group showed a greater reduction in both systolic (-4.9 mmHg) and diastolic (-3.3 mmHg) blood pressure compared to the control group.
  • Reductions were statistically significant (p=0.02 for systolic, p=0.04 for diastolic).
  • No serious adverse events were reported, indicating an acceptable safety profile.

Conclusions:

  • Combining probiotics with conventional antihypertensive drugs significantly reduces blood pressure in children with primary hypertension.
  • Probiotics offer a safe and effective complementary treatment option for pediatric hypertension.
Abstract

Keywords:
Antihypertensive treatmentEfficacyMicrobiomePediatric primary hypertensionProbiotics, Safety

More Related Videos

Investigating the Effects of Probiotics on Pneumococcal Colonization Using an In Vitro Adherence Assay09:20

Investigating the Effects of Probiotics on Pneumococcal Colonization Using an In Vitro Adherence Assay

Published on: April 28, 2014

12.7K
E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy06:28

E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy

Published on: August 1, 2019

8.4K

Related Concept Videos

Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
48
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
40
Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
3.1K
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
79
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.4K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
254